Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

AstraZeneca
Express Scripts
Merck
McKesson
Boehringer Ingelheim
Mallinckrodt

Last Updated: December 16, 2019

DrugPatentWatch Database Preview

BIMATOPROST Drug Profile

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

US ANDA Litigation and Generic Entry Outlook for Bimatoprost

A generic version of BIMATOPROST was launched as bimatoprost by APOTEX INC on December 16th, 2019.

Drug patent expirations by year for BIMATOPROST
Drug Prices for BIMATOPROST

See drug prices for BIMATOPROST

Drug Sales Revenue Trends for BIMATOPROST

See drug sales revenues for BIMATOPROST

Recent Clinical Trials for BIMATOPROST

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Sun Pharma Global FZEPhase 3
Laboratoires TheaPhase 3
Manistee PartnersPhase 2

See all BIMATOPROST clinical trials

Recent Litigation for BIMATOPROST

Identify potential future generic entrants

District Court Litigation
Case NameDate
DUKE UNIVERSITY v. AKORN, INC.2018-09-19
Duke University v. Alcon Laboratories, Inc.2018-05-01
Duke University v. Sandoz Inc.2018-04-26

See all BIMATOPROST litigation

Pharmacology for BIMATOPROST
Medical Subject Heading (MeSH) Categories for BIMATOPROST
Synonyms for BIMATOPROST
(5Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(1E,3S)-3-hydroxy-5-phenylpent-1-en-1-yl]cyclopentyl]-N-ethylhept-5-enamide
(5Z)-7-{(1R,2R,3R,5S)-3,5-dihydroxy-2-[(1E,3S)-3-hydroxy-5-phenylpent-1-en-1-yl]cyclopentyl}-N-ethylhept-5-enamide
(5z)-7-{(1r,2r,3r,5s)-3,5-Dihydroxy-2-[(1e,3s)-3-Hydroxy-5-Phenylpent-1-Enyl]cyclopentyl}-N-Ethylhept-5-Enamide
(E)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(E,3S)-3-hydroxy-5-phenylpent-1-enyl]cyclopentyl]-N-ethylhept-5-enamide
(Z)-7-((1R,2R,3R,5S)-3,5-Dihydroxy-2-((1E,3S)-3-hydroxy-5-phenyl-1-pentenyl)cyclopentyl)-N-ethyl-5-heptenamide
(Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((S,E)-3-hydroxy-5-phenylpent-1-en-1-yl)cyclopentyl)-N-ethylhept-5-enamide
(Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(E,3S)-3-hydroxy-5-phenyl-pent-1-enyl]cyclopentyl]-N-ethyl-hept-5-enamide
(Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(E,3S)-3-hydroxy-5-phenylpent-1-enyl]cyclopentyl]-N-ethylhept-5-enamide
155206-00-1
15M
17-PHENYL TRINOR PROSTAGLANDIN F2ALPHA ETHYL AMIDE
17-Phenyl-tri-norprostaglandin F2alpha-ethyl amide
17-Phenyl-tri-norprostaglandin F2alpha-ethyl amide, >=95%, solid
206B001
267244-98-4
5-Heptenamide, 7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((1E,3S)-3-hydroxy-5-phenyl-1-pentenyl)cyclopentyl)-N-ethyl-, (5Z)-
5-Heptenamide, 7-(3,5-dihydroxy-2-(3-hydrdoxy-5-phenyl-1-pentenyl)cyclopentyl)-N-ethyl-, (1R-(1alpha(Z),2beta(1E,3S*),3alpha,5alpha))-
5-Heptenamide, 7-(3,5-dihydroxy-2-(3-hydroxy-5-phenyl-1-pentenyl)cyclopentyl)-N-ethyl-, (1R-1(alpha(Z),2beta(1E,3S*)3alpha,5alpha))-
5-Heptenamide,7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((1E,3S)-3-hydroxy-5-phenyl-1-pentenyl)cyclopentyl)-N-ehtyl-,(5Z)
AB0015029
ABP000616
AC1NSJUW
AGN 192024
AGN-192024
AK173142
AKOS015995566
AM84507
AN-5283
AQOKCDNYWBIDND-FTOWTWDKSA-N
AS-35082
BDBM220120
Bimataprost [USAN:INN:BAN]
Bimatoprost (JAN/USAN/INN)
Bimatoprost [USAN:INN:BAN:JAN]
Bimatoprost/Lumigan
bimatoprostum
CHEBI:51230
CHEMBL1200963
CS-2085
D02724
DB00905
EX-A1769
GTPL1958
HY-B0191
I06-1275
I06-1277
Latisse
Latisse (TN)
LS-181817
Lumigan
Lumigan (TN)
M052
MLS006010039
MolPort-006-167-657
NCGC00181745-01
QXS94885MZ
RP17728
SCHEMBL24425
SMR000058996
SR-01000942224
SR-01000942224-1
UNII-QXS94885MZ
US9271961, Bimatoprost
ZINC4474405
Paragraph IV (Patent) Challenges for BIMATOPROST
Tradename Dosage Ingredient NDA Submissiondate
LUMIGAN SOLUTION/DROPS;OPHTHALMIC bimatoprost 022184 2011-04-05
LATISSE SOLUTION/DROPS;TOPICAL bimatoprost 022369 2010-05-03
LUMIGAN SOLUTION/DROPS;OPHTHALMIC bimatoprost 021275 2008-12-22

US Patents and Regulatory Information for BIMATOPROST

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Alembic Pharms Ltd BIMATOPROST bimatoprost SOLUTION/DROPS;OPHTHALMIC 210263-001 Apr 12, 2019 AT RX No No   Start Trial   Start Trial   Start Trial
Somerset Theraps Llc BIMATOPROST bimatoprost SOLUTION/DROPS;OPHTHALMIC 207601-001 Jun 19, 2019 AT RX No No   Start Trial   Start Trial   Start Trial
Hi-tech Pharma Co BIMATOPROST bimatoprost SOLUTION/DROPS;OPHTHALMIC 203299-001 Nov 8, 2018 DISCN No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Johnson and Johnson
Merck
Mallinckrodt
Boehringer Ingelheim
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.